Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02823470 · ClinicalTrials.gov registry record · Phase 4
A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation
A Phase 4 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Terminated
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT02823470 is a Phase 4 study that was terminated before completion, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 24 participants.
The verdict
NCT02823470, a Phase 4 study, was terminated before completion, sponsored by Vertex Pharmaceuticals Incorporated.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
The study will evaluate the impact of smart adherence technology for monitoring on lumacaftor/ivacaftor (LUM/IVA) adherence rates among subjects 16 years of age and older with Cystic Fibrosis (CF) who are homozygous for the F508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) mutation.
Interventions
- DRUG LUM/IVA
- DEVICE activated smart device
- DEVICE de-activated smart device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-06 |
| Est. Completion | 2017-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02823470
The ClinicalTrials.gov registry entry for NCT02823470 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which LUM/IVA is the first listed.
NCT02823470 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02823470 about?
NCT02823470 is a clinical study titled "A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation". The study will evaluate the impact of smart adherence technology for monitoring on lumacaftor/ivacaftor (LUM/IVA) adherence rates among subjects 16 years of age and older with Cystic Fibrosis (CF) who are homozygous for the F508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) mutation.
What is the current status of trial NCT02823470?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2016-06. Estimated completion is 2017-08.
What interventions are being tested in trial NCT02823470?
The interventions under investigation include: LUM/IVA (DRUG), activated smart device (DEVICE), de-activated smart device (DEVICE).
Who is sponsoring clinical trial NCT02823470?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.